This briefing from the NIHR Horizon Scanning Centre outlines the principles and purpose of the NeuroAD™ system, from Neuronix. NeuroAD™ is a non-invasive treatment for patients with mild and moderate Alzheimer’s Disease. which combines focused transcranial magnetic stimulation of the brain with cognitive training to target specific brain regions affected by the disease (as detected by MRI scans).
Research into the evaluation of the NeuroAD™ system is cited by this document. If proven to be clinically beneficial and cost-effective, NeuroAD™ promises to offer a new treatment option for patients with mild and moderate Alzheimer’s disease. According to Neuronix, early clinical trials indicate that the benefits of NeuroAD™ treatment might include increased cognitive function (in memory, concentration and language), with improved life-expectancy and potentially delayed deterioration to advanced Alzheimer’s Disease.
NeuroAD™ for mild and moderate Alzheimer’s Disease. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC), May 2013.
[A brief reference to this item features in Dementia and Elderly Care: the Latest Evidence Newsletter (RWNHST), Volume 3 Issue 9, August 2013].